Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240
血管生成生物标志物的发现可指导宫颈癌贝伐单抗治疗 - 基于血液的血管瘤分析:GOG-0240 的辅助分析
基本信息
- 批准号:10322184
- 负责人:
- 金额:$ 12.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiogenesis InhibitorsBiological MarkersBiological Response Modifier TherapyBloodCancer BurdenCancer PatientCessation of lifeClinicalCombination immunotherapyDevelopmentDiseaseEnrollmentEventFoundationsFutureGoalsGrowth FactorGynecologic Oncology GroupHealthcareHemangiomaHypertensionImmune responseImmunotherapyInflammationInflammatory ResponseInterleukin-6LaboratoriesMaintenanceMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of ovaryMalignant neoplasm of pancreasMeasuresOutcomePaclitaxelParticipantPatientsPhasePlasmaPredictive FactorProgression-Free SurvivalsProteinsRandomizedRecurrenceResearchResourcesRoleSamplingSignal PathwaySolid NeoplasmSpecimenStatistical Data InterpretationSystemTechnologyTestingToxic effectTumor AngiogenesisUnited States Food and Drug AdministrationWomanangiogenesisbasebevacizumabbiomarker discoverycancer therapycandidate markerchemotherapycostcost effectivecytokinedesignimprovedimproved outcomeinterestkidney cellnovelopen labelphase III trialplacebo controlled trialpredict clinical outcomepredictive markerprognosticprognostic of survivalresearch and developmentresponsesurvival outcometaxanetherapy developmentthrombotictreatment comparisontreatment grouptumor microenvironment
项目摘要
Project Summary
The anti-angiogenic agent bevacizumab (BEV) is one of the most effective forms of biologic therapy developed
thus far for cervical cancer (CC). However, response is variable, BEV is expensive, and significant toxicity may
occur. Given the projected increase in the global burden of cancer and limited health care resources, it is
imperative that research be conducted to define patients that will truly benefit from expensive therapies. The
development of an angiogenic biomarker to direct the use of BEV could maximize benefit, as well as minimize
toxicity and cost. My collaborator, Dr. Andrew Nixon, and his team at Duke have developed a protein-based
plasma multiplex array (angioma) that consists of 26 growth factors and cytokines involved in angiogenesis
and inflammation. We propose to evaluate our most promising biomarker, interleukin-6 (IL-6), which has
demonstrated predictive efficacy for BEV in other solid tumors, in women with advanced metastatic CC
enrolled on the Gynecologic Oncology Group (GOG) 240. Our primary aim is to determine if IL-6 levels can be
utilized to direct BEV therapy for women with CC. The pivotal phase III GOG-0240, a 2x2 bifactorial placebo-
controlled trial of taxane-based chemotherapy with and without BEV is the ideal platform to assess biomarkers.
Our specific aims will determine if (a) baseline IL-6 is predictive of BEV benefit based on survival outcomes, (b)
other angiome biomarkers are predictive and/or prognostic of survival outcomes in women with advanced CC
and c) angiome biomarker change is associated with outcome and response. Plasma samples at baseline and
pre-cycle 2 from GOG-0240 will be analyzed in Dr. Nixon’s laboratory using several multiplex systems
including technology from Quanterix Corporation, MesoScaleDiscovery, and Protein Simple (R&D Systems).
Statistical analyses will be performed to identify and validate biomarkers of interest. Kaplan-Meier plots and
log-rank tests will compare treatment groups. Our ultimate goal is to improve the outcome for women with CC
by rationally directing BEV therapy; minimizing toxicity and cost; and identifying novel targets to develop future
anti-angiogenic therapies. We anticipate that our research will help to harmonize analyses across other
malignancies, which will be critical for understanding if IL-6 and other candidate biomarkers predictive of BEV
efficacy are, or are not, disease specific.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW B. NIXON其他文献
Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure
循环血管生成素与慢性心力衰竭的逆向重构和预后相关
- DOI:
10.1016/j.cardfail.2022.12.011 - 发表时间:
2023-06-01 - 期刊:
- 影响因子:8.200
- 作者:
JOSEPHINE Harrington;ANDREW B. NIXON;MELISSA A. DAUBERT;ERIC YOW;JAMES JANUZZI;MONA FIUZAT;DAVID J. WHELLAN;CHRISTOPHER M. O'CONNOR;JUSTIN EZEKOWITZ;ILEANA L. PIÑA;KIRKWOOD F. ADAMS;G. MICHAEL FELKER;RAVI KARRA - 通讯作者:
RAVI KARRA
ANDREW B. NIXON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW B. NIXON', 18)}}的其他基金
The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center
杜克大学正常组织衰老细胞评估 (SCENT) 绘图中心
- 批准号:
10492746 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别:
Bridging SenNet and HuBMAP through spatial omics of the human intestine
通过人体肠道的空间组学桥接 SenNet 和 HuBMAP
- 批准号:
10895625 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别:
Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240
血管生成生物标志物的发现可指导宫颈癌贝伐单抗治疗 - 基于血液的血管瘤分析:GOG-0240 的辅助分析
- 批准号:
10112674 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别:
RGULATION OF CYCLIC GMP PHOSPHODIESTERASE BY GZ
广州市对环GMP磷酸二酯酶的规定
- 批准号:
6178844 - 财政年份:2000
- 资助金额:
$ 12.33万 - 项目类别:
RGULATION OF CYCLIC GMP PHOSPHODIESTERASE BY GZ
广州市对环GMP磷酸二酯酶的规定
- 批准号:
2709069 - 财政年份:1999
- 资助金额:
$ 12.33万 - 项目类别:
RGULATION OF CYCLIC GMP PHOSPHODIESTERASE BY GZ
广州市对环GMP磷酸二酯酶的规定
- 批准号:
6018420 - 财政年份:1999
- 资助金额:
$ 12.33万 - 项目类别:
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 12.33万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 12.33万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 12.33万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 12.33万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7615664 - 财政年份:2008
- 资助金额:
$ 12.33万 - 项目类别: